Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 385

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

Open access
Jin, Linchun, Tao, Haipeng, Karachi, Aida, Long, Yu, Hou, Alicia Y., Na, Meng, Dyson, Kyle A., Grippin, Adam J., Deleyrolle, Loic P., Zhang, Wang, Rajon, Didier A., Wang, Qiong J., Yang, James C., Kresak, Jesse L., Sayour, Elias J., Rahman, Maryam, Bova, Frank J., Lin, Zhiguo, Mitchell, Duane A., Huang, Jianping·2019·Nature Communications

Abstract

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days) intratumoral presentation of CAR T cells post-treatment is a superior predictor of survival than peripheral persistence. Therefore, we have co-opted IL-8 release from tumors to enhance intratumoral T-cell trafficking through a CAR design for maximal antitumor activity in solid tumors. Here, we demonstrate that IL-8 receptor, CXCR1 or CXCR2, modified CARs markedly enhance migration and persistence of T cells in the tumor, which induce complete tumor regression and long-lasting immunologic memory in pre-clinical models of aggressive tumors such as glioblastoma, ovarian and pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11869-4

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 385

Metadata

Authors
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Na, M., Dyson, K. A., Grippin, A. J., Deleyrolle, L. P., Zhang, W., Rajon, D. A., Wang, Q. J., Yang, J. C., Kresak, J. L., Sayour, E. J., Rahman, M., Bova, F. J., Lin, Z., Mitchell, D. A., & Huang, J.
Venue
Nature Communications
Published
2019-09-05
Volume
10
Issue
1
Pages
4016-4016
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2972117761
Cited by
385
References
50
FWCI
13.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. https://app.cochat.ai/papers/10.1038/s41467-019-11869-4
The paper
Jin, L., Tao, H., Karachi, A., Long, Y., Hou, A. Y., Na, M., Dyson, K. A., Grippin, A. J., Deleyrolle, L. P., Zhang, W., Rajon, D. A., Wang, Q. J., Yang, J. C., Kresak, J. L., Sayour, E. J., Rahman, M., Bova, F. J., Lin, Z., Mitchell, D. A., & Huang, J. (2019). CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nature Communications. https://doi.org/10.1038/s41467-019-11869-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.